SCHEMBL5879151

SCHEMBL5879151

O=C1C=C(c2c[nH]c3ccc(O)cc23)C(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.44
CYP2C9 P11712 2/20 0.42
TSHR P16473 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
NFKB1 P19838 1/20 0.42
PMP22 Q01453 1/20 0.42
PDGFRB P09619 1/20 0.41
KIT P10721 1/20 0.41
KDR P35968 1/20 0.41
HTR2C P28335 3/20 0.41
NR4A1 P22736 1/20 0.40
GAA P10253 1/20 0.40
HTR1A P08908 2/20 0.40
HTR2A P28223 2/20 0.40
HTR2B P41595 2/20 0.40
HTR3E A5X5Y0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879255 0.82 IGF1R (0.50) TSHRPDGFRBKITKDRHTR1A
SCHEMBL5879171 0.82 CLK1 (0.45) HPGDPDGFRBKITKDRHTR1D
SCHEMBL5879252 0.82 PDGFRB (0.50) PDGFRBKITKDRHTR1AHTR2A
SCHEMBL5879259 0.82 KDM4E (0.44) LMNAPDGFRBHTR1AHTR2AHTR1D
SCHEMBL5879170 0.82 F7 (0.45) CYP2C9ALDH1A1HTR1AHTR2ACYP1A2
SCHEMBL10433674 0.79 JAK2 (0.46) ALDH1A1PDGFRBKITKDRGAA
SCHEMBL10433699 0.79 HTR3E (0.42) TSHRALDH1A1HPGDPDGFRBKIT
SCHEMBL5879148 0.79 KDR (0.57) NPSR1ALDH1A1LMNAPDGFRBKDR
SCHEMBL10433665 0.79 IDO1 (0.46) ALDH1A1HPGDHTR1ACYP1A2HTR7
SCHEMBL2193383 0.78 PRKCB (0.65) BRAFPDGFRBKITKDRPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 BRAF 2665/4885CYP2C9 1405/4885TSHR 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.